Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial

Abstract Prognosis of adult patients with relapsed/refractory (r/r) or measurable residual disease (MRD)–positive B-precursor acute lymphoblastic leukemia (B-ALL) remains poor. Blinatumomab induces complete remissions (CR) and MRD negativity in a subset of patients, yet overall survival remains limi...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Lars Fransecky, Walter Fiedler, Christoph Röllig, Tim Sauer, Simon Raffel, Winfried Alsdorf, Lisa Heberling, Britta Steer, Karin Huber, Tim Versteegen, Lea Spory, Dorothee Deckbar, Lena Reiser, Sonja Bendig, Lorenz Bastian, Cecilia Bozzetti, Thomas Beder, Martin Neumann, Monika Brüggemann, Nicola Gökbuget, Claudia Baldus
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Springer 2026-02-01
Sarja:	Annals of Hematology
Aiheet:	Acute leukemia Acute lymphoblastic leukemia (ALL) Venetoclax Blinatumomab Bispecific antibody BH3 mimetics
Linkit:	https://doi.org/10.1007/s00277-026-06883-8
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!